Comparative Pharmacology
Head-to-head clinical analysis: ADMELOG versus NOVOLIN R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADMELOG versus NOVOLIN R.
ADMELOG vs NOVOLIN R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that binds to the insulin receptor, activating downstream signaling pathways to facilitate cellular glucose uptake, inhibit hepatic gluconeogenesis, and promote glycogen synthesis, lipogenesis, and protein synthesis.
Regular insulin lowers blood glucose by promoting peripheral glucose uptake, especially in skeletal muscle and adipose tissue, and by inhibiting hepatic glucose production. It binds to insulin receptors on cell membranes, activating tyrosine kinase activity and downstream signaling pathways that regulate glucose transport and metabolism.
Subcutaneous injection: 0.2-1.0 units/kg/day divided into 2-4 doses. Typical starting dose: 0.4-0.6 units/kg/day. Administer within 15 minutes before or immediately after a meal.
Subcutaneous: 0.5-1 unit/kg/day divided into 2-3 doses; intravenous: continuous infusion starting at 0.05-0.1 units/kg/hr adjusted based on blood glucose.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2.5 hours (subcutaneous administration). This short half-life reflects rapid absorption and clearance, suitable for prandial glucose control.
Intravenous: 5-10 minutes (short due to rapid distribution and degradation). Subcutaneous: 1-2 hours (terminal half-life after absorption).
Renal (primarily as unchanged drug, following degradation by insulin-degrading enzyme). Approximately 60-80% of a dose is excreted renally; the remainder is metabolized in the liver and kidneys.
Renal (tubular reabsorption and metabolism). Approximately 50-80% of insulin is degraded in the liver and kidneys; the remainder is excreted in urine as metabolites and intact hormone (<1%).
Category C
Category C
Insulin
Insulin